Description

Early/Managed/Expanded access programmes in Europe have varying legislations and sponsor company interpretations adding a layer of complexity. This has created a need for a forum where companies can exchange ideas and learn from each other’s experiences in order to run successful EAPs across the continent. The 2nd Operationalise: Early Access Programmes Europe Summit is the only forum that will give you the actionable solutions to run access programmes the in 20+ European Countries. Dive deeper into real-world data collection, supply, and compliance, with dedicated sessions covering both ‘the big 5’ alongside Eastern European countries. Leave with questions answered and new ideas on setting up, running, and closing out access programmes.

The 2nd Operationalise Early Access Programmes Summit Europe continues to tackle the industry’s most pressing issues, around drug supply, regulatory harmonisation, real-world evidence collection, while also exploring emerging challenges such as reimbursement, integrating of pre- and post-trial access programmes and scoping.

With each speaker sharing the same desire to increase the access for patients, by sharing practical solutions to operational challenges, ensure that you are part of this timely conversation. This meeting will equip you with actionable insights and valuable connections to enhance patient access in 2023 and beyond.

 

 

URLs:
Website: https://go.evvnt.com/1768476-0?pid=10007
Brochure: https://go.evvnt.com/1768476-2?pid=10007

Prices:
Drug Developers | Conference + 3 Workshops: GBP 3896.00,
Drug Developers | Conference + 2 Workshops: GBP 3397.00,
Drug Developers | Conference + 1 Workshop: GBP 2898.00,
Drug Developers | Conference only: GBP 2399.00,
Solution Provider | Conference + 3 Workshops: GBP 4646.00,
Solution Provider | Conference + 2 Workshops: GBP 4097.00,
Solution Provider | Conference + 1 Workshop: GBP 3548.00,
Solution Provider | Conference only: GBP 2999.00

 

Speakers: Alita Hassan | Vice President | Early Access Care, Amber Fisher | Clinical Research Manager | Kura Oncology, Anna Litsiou | Regulatory Policy and Intelligence Director – International and China | AstraZeneca, Anne Cropp | Chief Scientific Officer | Early Access Care, Annie Drelles | Director and Head of Office of Medical Access, Global Oncology and Medical Affairs | Daiichi Sankyo, Inc., Annie O’Keefe Martin | Global Medical Governance Managed Access and Humanitarian Programs – Specialty Care | Sanofi, Blake Morrison | Vice President and Head of Global Medical and Scientific Affairs | Sumitomo Pharma Oncology, Inc., Carolina Cela Ramos | Medical Affairs Operations Manager | Incyte Biosciences, Cassandra Slader | Global Head of Managed Access Programs, Global Medical Affairs | UCB, Dennis Akkaya | Chief Commercial Officer | myTomorrows, Dr. Alberto Calabro’| Patient Access and Supply Leader | Roche, Dr. Philipp Schlatter | Community of Practice Leader Patient Access Programs and Drug Supply Global Medical Affairs | Roche, Gino Van Dooren | EMEA Medical Program Lead Neurosciences | Johnson and Johnson, Gunnar Schroefel | Global Director Patient Advocacy | Daiichi Sankyo Europe GmbH, Julie Powell | Communications Director | Pleco Therapeutics BV, Michael Hotze | Director Medical Affairs Operations Europe | Incyte Biosciences, Nicola Gillott | Head of Expanded Access | Amryt Pharma, Pedro Franco | Director Europe for Global Regulatory and Scientific Policy Merck | Serono, Pierre Cherubin | Medical Program, Oncology and Hematology Manager | Johnson and Johnson, Ramona Reichenbach | Head Managed Access Center of Excellence | Novartis, Robert Mitchell-Thain | Chief Executive Officer | The PBC Foundation Ltd., Ruhe Chowdhury | Medical Affairs, Honorary Consultant Medical Oncologist | Pfizer, Sara Radenovic | Director – Managed Access Programs | GSK, Sheela Upadhyaya | Chair Rare Disease Special Interest Group | ISPOR, Vilem Guryca | Associate Director, Expanded Access, Global Medical Affairs | BeiGene